000285365 001__ 285365
000285365 005__ 20260302100429.0
000285365 0247_ $$2doi$$a10.1016/S0140-6736(25)02365-7
000285365 0247_ $$2pmid$$apmid:41763745
000285365 0247_ $$2ISSN$$a0140-6736
000285365 0247_ $$2ISSN$$a0023-7507
000285365 0247_ $$2ISSN$$a1474-547X
000285365 037__ $$aDZNE-2026-00229
000285365 041__ $$aEnglish
000285365 082__ $$a610
000285365 1001_ $$aSchneider-Thoma, Johannes$$b0
000285365 245__ $$aComparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases.
000285365 260__ $$aLondon [u.a.]$$bElsevier$$c2026
000285365 3367_ $$2DRIVER$$aarticle
000285365 3367_ $$2DataCite$$aOutput Types/Journal article
000285365 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1772442147_18951
000285365 3367_ $$2BibTeX$$aARTICLE
000285365 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285365 3367_ $$00$$2EndNote$$aJournal Article
000285365 520__ $$aAntipsychotic drugs are the established treatment for acute schizophrenia but differ in receptor-binding profiles. In 2024, a new-in-class muscarinic receptor agonist (xanomeline-trospium) was licenced, acting upstream of antidopaminergic agents, and providing hope to decrease the adverse effects burden of antipsychotics. We aimed to compare the efficacy and tolerability of antipsychotics by performing network meta-analysis of randomised controlled trials (RCTs).This systematic review (PROSPERO, CRD42022380708) included blinded and open RCTs investigating antipsychotic drugs in participants of any age with acute psychotic symptoms of schizophrenia over 3 weeks to 3 months. Included antipsychotics comprised 23 primarily dopamine-receptor blocking medications and the muscarinic receptor agonist xanomeline-trospium in different applications. We searched Cochrane Schizophrenia group's register, previous reviews, and five Chinese databases for trials published from database inception until July 26, 2024 and contacted authors to assess trials' methodological quality; only trials with appropriate randomisation indicated were included. The primary outcome was rating scale-measured overall symptoms of schizophrenia (efficacy) analysed with random-effects frequentist network meta-analysis. Secondary outcomes comprised 32 further efficacy and tolerability outcomes. The confidence in the estimates was assessed using the Confidence in Network Meta-Analysis approach.After screening 18 859 references and contacting authors of 5428 trials, we included 438 RCTs. Of those, 388 RCTs with 78 193 participants (28 448 women and 49 745 men) provided usable data for at least one outcome. 5117 Chinese trials were identified but most were excluded because authors did not reply or reported serious methodological concerns. 256 double-blind studies with 58 948 participants provided usable data for the primary outcome. All antipsychotics reduced symptoms more than placebo with standardised mean differences ranging from -0·90 (95% CI -1·03 to -0·77) to -0·23 (-0·39 to -0·06). Particularly clozapine, as well as amisulpride, olanzapine, and risperidone were more efficacious than at least three other antipsychotics (confidence in estimates were low-to-moderate). Adverse effects varied across medications.This network meta-analysis provides evidence for small-to-medium clinically relevant differences between antipsychotics in efficacy; this finding warrants stronger and more specific emphasis in clinical guidelines. Nonetheless, important differences in tolerability need to be considered for individualised drug choice, with partial dopamine agonists having overall better tolerability and xanomeline-trospium lacking adverse effects of dopamine-blocking agents but resulting in cholinergic and anticholinergic adverse events. Future research should directly compare xanomeline-trospium with other antipsychotics to confirm its efficacy; modern trials using clozapine early in schizophrenia are needed to establish whether it improves outcomes and prevents chronification.German Research Foundation, German Ministry of Research, Technology and Space, and National Natural Science Foundation of China.
000285365 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285365 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285365 7001_ $$aZhu, Yikang$$b1
000285365 7001_ $$aQin, Mengchang$$b2
000285365 7001_ $$aDong, Yu$$b3
000285365 7001_ $$aGuan, Shiwei$$b4
000285365 7001_ $$aWang, Jiaxi$$b5
000285365 7001_ $$aTian, Jing$$b6
000285365 7001_ $$aLin, Xiao$$b7
000285365 7001_ $$aRodolico, Alessandro$$b8
000285365 7001_ $$aSiafis, Spyridon$$b9
000285365 7001_ $$aBighelli, Irene$$b10
000285365 7001_ $$aWehner, Melanie$$b11
000285365 7001_ $$aVeith, Christina$$b12
000285365 7001_ $$aKrayer, Felix$$b13
000285365 7001_ $$aScheuring, Elfriede$$b14
000285365 7001_ $$aDavis, John M$$b15
000285365 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b16$$udzne
000285365 7001_ $$aNikolakopoulou, Adriani$$b17
000285365 7001_ $$aSalanti, Georgia$$b18
000285365 7001_ $$aLi, Chunbo$$b19
000285365 7001_ $$aLeucht, Stefan$$b20
000285365 773__ $$0PERI:(DE-600)1476593-7$$a10.1016/S0140-6736(25)02365-7$$gVol. 407, no. 10531, p. 876 - 891$$n10531$$p876 - 891$$tThe lancet$$v407$$x0140-6736$$y2026
000285365 8564_ $$uhttps://pub.dzne.de/record/285365/files/DZNE-2026-00229.pdf$$yRestricted
000285365 8564_ $$uhttps://pub.dzne.de/record/285365/files/DZNE-2026-00229.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285365 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000285365 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285365 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-12$$wger
000285365 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET : 2022$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-12
000285365 915__ $$0StatID:(DE-HGF)9990$$2StatID$$aIF >= 90$$bLANCET : 2022$$d2025-11-12
000285365 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x0
000285365 980__ $$ajournal
000285365 980__ $$aEDITORS
000285365 980__ $$aVDBINPRINT
000285365 980__ $$aI:(DE-2719)5000007
000285365 980__ $$aUNRESTRICTED